Angiogenesis is regulated in a tissue-specific manner in all patients, especially those with diabetes. In this study, we describe a novel molecular pathway of angiogenesis regulation in diabetic rats with
myocardial infarction (MI) and examine the cardioprotective effects of different doses of
sitagliptin. Male rats were divided into 5 groups: normal vehicle group, diabetic group, diabetic + MI, diabetic + MI + 5 mg/kg
sitagliptin, and diabetic + MI + 10 mg/kg
sitagliptin.
Isoproterenol in diabetic rats resulted in significant (p < 0.05) disturbance to the electrocardiogram, cardiac histopathological manifestations, and an increase in inflammatory markers compared with the vehicle and diabetic groups. Treatment with
sitagliptin improved the electrocardiogram and histopathological sections, upregulated
vascular endothelial growth factor (
VEGF) and transmembrane phosphoglycoprotein
protein (CD34) in cardiac tissues, and increased serum
insulin-like growth factor 1 (IGF-1) and decreased cardiac tissue homogenate for
interleukin 6 (IL-6) and
cyclooxygenase 2 (COX-2). A relationship was found between serum
IGF-1 and cardiac
VEGF and CD34 accompanied by an improvement in cardiac function of diabetic rats with MI. Therefore, the observed effects of
sitagliptin occurred at least partly through an improvement in angiogenesis and the mitigation of
inflammation. Consequently, these data suggest that
sitagliptin may contribute, in a dose-dependent manner, to protection against acute MI in diabetic individuals.